Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$18.30
+0.9%
$20.24
$10.21
$25.67
$4.37B0.433.69 million shs1.05 million shs
La Jolla Pharmaceutical stock logo
LJPC
La Jolla Pharmaceutical
$5.73
$3.07
$6.24
$155.11M2.39158,476 shs66,708 shs
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
$7.30
+0.7%
$2.06
$0.26
$3.77
$191.84M2.06168,718 shs73,796 shs
Novavax, Inc. stock logo
NVAX
Novavax
$6.80
+0.5%
$6.76
$5.01
$17.81
$1.10B2.696.28 million shs2.29 million shs
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
$2.91
+4.5%
$3.18
$1.60
$10.48
$112.11M1.35796,678 shs133,655 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
0.00%+0.74%-11.23%-0.57%+59.64%
La Jolla Pharmaceutical stock logo
LJPC
La Jolla Pharmaceutical
0.00%0.00%0.00%0.00%0.00%
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
0.00%+9.77%+5.19%+5.95%+26.41%
Novavax, Inc. stock logo
NVAX
Novavax
0.00%+6.67%-8.79%+3.90%-42.90%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
0.00%+0.90%-12.99%-21.46%+40.39%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
4.1602 of 5 stars
3.72.00.00.03.02.53.1
La Jolla Pharmaceutical stock logo
LJPC
La Jolla Pharmaceutical
N/AN/AN/AN/AN/AN/AN/AN/A
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
1.4312 of 5 stars
0.04.00.04.70.60.80.6
Novavax, Inc. stock logo
NVAX
Novavax
4.497 of 5 stars
3.12.00.04.71.30.83.1
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
1.8027 of 5 stars
3.61.00.00.01.70.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3.33
Buy$27.6751.23% Upside
La Jolla Pharmaceutical stock logo
LJPC
La Jolla Pharmaceutical
0.00
N/AN/AN/A
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
0.00
N/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
2.29
Hold$17.00150.18% Upside
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3.14
Buy$20.50605.44% Upside

Current Analyst Ratings Breakdown

Latest ADMA, LJPC, LOGC, TARA, and NVAX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Novavax, Inc. stock logo
NVAX
Novavax
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSell$6.00
5/22/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$21.00
5/19/2025
Novavax, Inc. stock logo
NVAX
Novavax
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/9/2025
Novavax, Inc. stock logo
NVAX
Novavax
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$9.00 ➝ $7.00
5/8/2025
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.00
4/28/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
4/16/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$12.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$426.45M10.24$0.54 per share33.77$1.48 per share12.36
La Jolla Pharmaceutical stock logo
LJPC
La Jolla Pharmaceutical
$75.72M0.00N/A7.95($2.94) per share0.00
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
$287M0.67N/AN/A$8.96 per share0.81
Novavax, Inc. stock logo
NVAX
Novavax
$682.16M1.61N/AN/A($3.89) per share-1.75
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/AN/AN/AN/A$4.77 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$197.67M$0.8521.5226.51N/A45.01%47.16%30.51%8/6/2025 (Estimated)
La Jolla Pharmaceutical stock logo
LJPC
La Jolla Pharmaceutical
$19.66M$0.1251.840.00N/A8.54%-5.46%4.00%N/A
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
-$317M-$5.79N/AN/A-141.03%-81.98%-52.13%N/A
Novavax, Inc. stock logo
NVAX
Novavax
-$187.50M$2.652.5684.940.0638.14%-115.51%29.99%8/14/2025 (Estimated)
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$44.60M-$1.72N/AN/AN/AN/A-36.37%-33.29%8/5/2025 (Estimated)

Latest ADMA, LJPC, LOGC, TARA, and NVAX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
N/A-$0.27N/A-$0.27N/AN/A
5/8/2025Q1 2025
Novavax, Inc. stock logo
NVAX
Novavax
$0.71$2.93+$2.22$2.93$204.08 million$666.66 million
5/8/2025Q1 2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$0.47-$0.29+$0.18-$0.29N/AN/A
5/7/2025Q1 2025
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$0.16$0.14-$0.02$0.11$116.40 million$114.80 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
N/AN/AN/AN/AN/A
La Jolla Pharmaceutical stock logo
LJPC
La Jolla Pharmaceutical
N/AN/AN/AN/AN/A
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
0.22
6.58
3.36
La Jolla Pharmaceutical stock logo
LJPC
La Jolla Pharmaceutical
N/A
4.02
3.52
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
N/A
31.60
31.60
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.06
2.03
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/A
18.03
18.03

Institutional Ownership

CompanyInstitutional Ownership
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
75.68%
La Jolla Pharmaceutical stock logo
LJPC
La Jolla Pharmaceutical
97.06%
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
46.05%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
38.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
530238.73 million229.90 millionOptionable
La Jolla Pharmaceutical stock logo
LJPC
La Jolla Pharmaceutical
6124.94 million15.89 millionOptionable
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
6226.28 million24.16 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990161.97 million160.35 millionOptionable
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3038.58 million33.76 millionOptionable

Recent News About These Companies

Protara Therapeutics, Inc. (TARA) - Yahoo Finance
Analysts Set Expectations for TARA FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA Biologics stock logo

ADMA Biologics NASDAQ:ADMA

$18.30 +0.16 (+0.85%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$18.33 +0.03 (+0.19%)
As of 06:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

La Jolla Pharmaceutical stock logo

La Jolla Pharmaceutical NASDAQ:LJPC

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.

LogicBio Therapeutics stock logo

LogicBio Therapeutics NASDAQ:LOGC

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Novavax stock logo

Novavax NASDAQ:NVAX

$6.80 +0.04 (+0.52%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$6.80 0.00 (0.00%)
As of 06:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Protara Therapeutics stock logo

Protara Therapeutics NASDAQ:TARA

$2.91 +0.13 (+4.53%)
Closing price 07/3/2025 03:23 PM Eastern
Extended Trading
$2.88 -0.02 (-0.72%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.